Matching-Adjusted Indirect Comparisons of Efficacy Outcomes in Patients with Relapsed and Refractory Multiple Myeloma for Idecabtagene Vicleucel (KarMMa) Versus Selinexor Plus Dexamethasone (STORM Part 2) and Belantamab Mafodontin (DREAMM-2): Updated Analysis with Longer Follow-up
- Resource Type
- Article
- Source
- Blood; November 2021, Vol. 138 Issue: 1, Number 1 Supplement 1 p1978-1978, 1p
- Subject
- Language
- ISSN
- 00064971; 15280020